CROMSOURCE, an international contract research organization (CRO) with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf of a European pharmaceutical company.
The Montreal Heart Institute (MHI) Research Centre has collaborated with New York City’s NYU Grossman School of Medicine for a new COVID-19 clinical study.
GlaxoSmithKline (GSK) said that its asthma drug Nucala (mepolizumab) has succeeded in the phase 3 SYNAPSE trial in patients with nasal polyps associated with chronic rhinosinusitis (CRSwNP).
Zymeworks announced that its partner, BeiGene has dosed the first patient in a two-arm Phase 1b/2 trial evaluating the former's HER2-targeted bispecific antibody ZW25 in combination with chemotherapy as a first-line treatment for patients with metastatic HER2-positive breast cancer and in combination with chemotherapy and BeiGene’s PD-1-targeted antibody tislelizumab as a first-line treatment for patients with metastatic HER2-positive gastroesophageal adenocarcinoma (GEA).
Concert Pharmaceuticals announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.
Noveome Biotherapeutics has launched a new programme to assess its ST26 product candidate for the treatment of the severe inflammatory cytokine storm response associated with COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
Merck said that its orally administered soluble guanylate cyclase (sGC) stimulator vericiguat met the primary efficacy endpoint in the phase 3 VICTORIA trial in heart failure patients.
AVEO Oncology and Biodesix announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML).
AveXis said that a one-time infusion of Zolgensma (onasemnogene abeparvovec-xioi) delivered rapid, substantial, and clinically meaningful therapeutic benefit in spinal muscular atrophy (SMA) patients across a range of trials.
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA (venetoclax) in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints of statistically significant improvement of overall survival (OS) and composite complete remission rate (CR + CRi) for patients with previously-untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.